When less is more - efficacy with less toxicity at the ED50
- PMID: 28387051
- PMCID: PMC5465328
- DOI: 10.1111/bcp.13281
When less is more - efficacy with less toxicity at the ED50
Keywords: dose-response; effective dose 50; pharmaceutical marketing.
Figures
References
-
- Peck C, Urquhart J. Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980‐1999. Pharmacoepidemiol Drug Saf 2002; 11: 439–446. - PubMed
-
- Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980‐1999. Pharmacoepidemiol Drug Saf 2002; 11: 439–446. - PubMed
-
- Martin JH, Fay MF. Surrogate end‐points in clinical practice: are we providing worse care? Intern Med J 2010; 40: 395–398. - PubMed
-
- Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrback K, et al. Bariatric surgery. A systematic review and meta‐analysis. JAMA 2004; 292: 1724–1737. - PubMed
-
- Vamos M, Erath JW, Hohnloser SH. Digoxin‐associated mortality: a systematic review and meta‐analysis of the literature. Eur Heart J 2015; 36: 1831–1838. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources